Teneligliptin Hydrobromide Teneligliptin HBr CAS 906093-29-6 CAS 906093-29-6 Purity >99.5% (HPLC) DPP-4 Inhibitor Factory

Short Description:

Chemical Name: Teneligliptin Hydrobromide

Synonyms: Teneligliptin HBr

CAS: 906093-29-6

Purity: >99.5% (by HPLC)  

Assay: 99.5%~102.0% (Anhydrous Substance)

Appearance: White or Off-White Powder

API DPP-4 inhibitor in the treatment of Type 2 diabetes

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name Teneligliptin Hydrobromide
Synonyms Teneligliptin HBr
CAS Number 906093-29-6
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C22H32.5N6OSBr2.5
Molecular Weight 628.86
Brand Ruifu Chemical

Specifications:

Items Standards Results
Characteristics White or Off-White Powder Complies
Identification By IR Complies
  By HPLC Complies
Water Content (K.F.) <6.00% 3.00%
Residue on Ignition <0.50% 0.10%
Heavy Metals (as Pb) <20ppm Complies
Related Substances Any Single Impurity: <0.10% 0.05%
  Total Impurities: <0.50% 0.15%
Purity / Analysis Method >99.5% (by HPLC) 99.85%
Assay 99.5%~102.0% (Anhydrous Substance)   99.90%
Test Standard Enterprise Standard
Conclusion The Product Complied to In-House Standard.

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

Teneligliptin Hydrobromide (CAS: 906093-29-6) is a dipeptidyl peptidase-4 (DPP-4) inhibitor that is used to treat type 2 diabetes. It is eliminated via excretion, and has a half-life of 24.2 hours in the human body. Teneligliptin is a DPP-4 inhibitor which was approved in Japan in 2012 for the treatment of type II diabetes. It was discovered and developed by Mitsubishi Tanabe Pharma under the trade name Tenelia®. Similar to other marketed DPP-4 inhibitors, teneligliptin was well tolerated in all studies and QD dosing produced a long-lasting inhibitory action against DPP-4 and an increase in active GLP-1 levels, with very low rates of renal excretion. 

  • Write your message here and send it to us